At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Ticagrelor +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Single Dose Study to Evaluate the Effect of BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Patients With Stable Coronary Artery Disease and Healthy Participants
In Brief
A Phase 2 clinical trial evaluating Ticagrelor, BMS-986141, and 1 other intervention for Coronary Artery Disease and Healthy Participants. Completed, enrolled 58 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable coronary artery disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Healthy Participants
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartMar 2022
Primary CompletionNov 2022
TodayJul 2026
First PostedOct 26, 2021
Enrollment StartMar 25, 2022
Primary CompletionNov 14, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.7 years ago
Interventions
Ticagrelordrug
Specified dose on specified days
BMS-986141drug
Specified dose on specified days
Aspirindrug
Specified dose on specified days